News
Rilzabrutinib is a promising treatment option for patients with chronic spontaneous urticaria who are refractory to antihistamines.
SAN DIEGO — Phase 3 data support rilzabrutinib as a potential first-in-class oral Bruton tyrosine kinase (BTK) inhibitor for patients with previously treated immune thrombocytopenia (ITP).
Patients with immune thrombocytopenia achieved durable platelet count expansion with rilzabrutinib. Rilzabrutinib exhibited a safety profile comparable to placebo. SAN DIEGO — Rilzabrutinib ...
Rilzabrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), demonstrated a rapid and substantial alleviation of symptoms in patients with chronic spontaneous urticaria (CSU) unresponsive to ...
Hosted on MSN1mon
SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare DiseasesSNY's Rilzabrutinib Under Review for Immune Thrombocytopenia Sanofi has developed rilzabrutinib for treating immune thrombocytopenia (“ITP”), another rare, complex autoimmune disorder. A ...
Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy ...
Rilzabrutinib significantly alleviates itch and hives in patients with CSU unresponsive to H1-antihistamines, offering a potential new treatment option. The RILECSU trial demonstrated significant ...
5mon
GlobalData on MSNSanofi’s Phase III trial of rilzabrutinib for thrombocytopenia meets endpointSanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib for the treatment of persistent or chronic immune ...
Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib. Patients experienced rapid improvement ...
Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under regulatory review in the US, EU and China for potential use in immune ...
Positive results from the pivotal LUNA 3 phase 3 study of rilzabrutinib in adults with persistent or chronic immune thrombocytopenia (ITP), a rare immune-mediated disease, reinforce the efficacy and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results